The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

Core Viewpoint - The company is expected to achieve a product net revenue of $470 million in 2025, representing a year-on-year increase of 16.5% [1] Financial Projections - Core product Efgartigimod (FcRn) revenue is projected to be $97.96 million in 2025, with a gross margin of 61.0% [1] - R&D expenses are anticipated to be $200 million, a decrease of 12.8% year-on-year, while SG&A expenses are expected to be $280 million, down 5.0% year-on-year [1] - The company is projected to incur a net loss of $180 million in 2025, an improvement from a net loss of $260 million in the previous year [1] Strategic Insights - The management reiterated a dual-driven strategy focusing on introducing high-quality overseas products for domestic commercialization, which provides a solid financial foundation for global innovation investments [1] - The company has a rich portfolio of commercialized products in the domestic market, with eight products approved for launch, and several differentiated global assets in the pipeline [1] Clinical Development Updates - Zocilurtatug (DLL3 ADC) is expected to initiate three registration clinical studies by the end of 2026, with a focus on small cell lung cancer and neuroendocrine cancer [2] - Multiple early-stage clinical products are anticipated to contribute to long-term global value, including ZL-1503 for atopic dermatitis, ZL-6201 for various solid tumors, ZL-1222 for enhanced anti-tumor activity, and ZL-1311 for gastric cancer [3] Valuation Adjustments - Revenue forecasts for 2025-2027 have been adjusted to $470 million, $500 million, and $720 million respectively, reflecting a downward revision from previous estimates [3] - Net profit forecasts for the same period have also been revised to -$180 million, -$160 million, and -$60 million respectively [3] - The company is valued using a DCF model with a WACC of 9.9% and a perpetual growth rate of 2.0%, resulting in a target price of HKD 35.25, maintaining an "outperform" rating [3]

Zai Lab Limited (NASDAQ:ZLAB) ranks among the best high growth Chinese stocks to buy. On January 7, UBS began coverage of Zai Lab Limited (NASDAQ:ZLAB) with a Buy rating and a $35 price target, citing the company’s transition from a China-centric commercial strategy to a global innovation powerhouse. The firm views Zai Lab Limited (NASDAQ:ZLAB) as a distinct biopharma platform poised for long-term global expansion by leveraging its strong China-based business while developing a pipeline of fully owned canc ...

Investment Rating - The report maintains an "Outperform" rating for Zai Lab with a target price of HKD 35.25, indicating an expected return exceeding the market benchmark over the next 12-18 months [2][19]. Core Insights - Zai Lab is projected to achieve product net revenue of USD 465 million in FY25, representing a year-on-year growth of 16.5%. The core product, efgartigimod, is expected to generate USD 97.96 million, with a gross profit margin of 61.0% [3][16]. - The management emphasizes a dual-engine strategy focusing on introducing high-quality overseas products for commercialization in China and leveraging a cross-border R&D platform for efficient global market development [4][17]. - Despite a downward revision in revenue guidance for 2025 and a delay in profitability targets, the company has a robust portfolio with eight products approved in China and several differentiated global assets in its pipeline [4][17]. Financial Performance - Revenue forecasts for FY25-FY27 have been adjusted to USD 465 million, USD 501 million, and USD 717 million, respectively. Net loss estimates for the same period are revised to USD 180 million, USD 159 million, and USD 55 million [10][19]. - R&D expenses are expected to be USD 205 million, a decrease of 12.8% year-on-year, while SG&A expenses are projected at USD 284 million, down 5.0% [3][16]. Clinical Development Pipeline - Zocilurtatug (DLL3 ADC) is set to initiate three registrational clinical trials by the end of 2026, targeting small cell lung cancer and neuroendocrine carcinoma [5][21]. - Several early-stage products, including ZL-1503 for atopic dermatitis and ZL-6201 for various solid tumors, are anticipated to contribute to long-term global value [6][9][21].

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their products, with significant business development (BD) transactions announced[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% increase year-on-year, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise, with a projected increase of 33-38% for NAND Flash products due to supply constraints[36] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - The goal is to achieve a 30% share of renewable energy in total power generation by 2030, indicating significant growth potential for the solar and wind energy sectors[46]

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their advancements, with significant business development (BD) transactions reported[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% year-on-year increase, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise due to increased demand from AI servers, with NAND Flash supply expected to decrease by 41.7% in 2026[35] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - By 2030, renewable energy generation is expected to account for approximately 30% of total power generation, indicating significant growth potential in the solar and wind sectors[46]

格隆汇1月27日丨根据联交所最新权益披露资料显示，2026年1月21日，再鼎医药(09688.HK)获JPMorgan Chase & Co.以每股均价14.6037港元增持好仓615.01 万股，涉资约8981.44万港元。 | 股份代號: | | --- | | 上市法國名稱: | | 日期(日/月/年 | | | (股東/董事/最高行政人員名稱作出披露的 冒入/曹出或涉及的 | | | 图段的平均值 | 符有權益的股份數目 | 佔已發行的 有關事件的日 | | --- | --- | --- | --- | --- | --- | --- | | | 校 7 31 三 | | | | 語参閱 「亦 * 註 | 有投票權版(日/月/年) 行营分证 | | CS20260126E00448 | JPMorgan Chase & Co. | 1001(L) | 6.150,110(L) | HKD 14.6037 | 59.526.621(L | 5.31(L)21/01/2026 | | | | 1403(S) | 1,233,010(S) | | 35.952,475(S) | 3.21(S) | | | ...

Market Performance - The three major U.S. stock indices closed higher on Monday, with the Dow Jones up 0.64% at 49,412.4 points, the S&P 500 up 0.5% at 6,950.23 points, and the Nasdaq up 0.43% at 23,601.36 points [1][2]. Company Updates - Major tech stocks mostly rose, with Apple increasing nearly 3% as it plans to announce a new version of Siri in late February, following a partnership with Google due to internal AI model challenges [2]. - Facebook rose over 2%, Google increased over 1%, while Tesla fell over 3% and Nvidia dropped 0.64% [2]. Earnings Season Insights - Over 90 companies in the S&P 500 are set to report quarterly earnings this week, including major players like Microsoft, Meta, Tesla, and Apple. So far, 76% of the companies that have reported exceeded earnings expectations [3]. - Investors are particularly interested in details regarding AI plans, investment speeds, and expected profits to assess the sustainability of the current bull market [3]. Semiconductor Sector - The Philadelphia Semiconductor Index fell by 0.39%, with Intel dropping over 5.7% after a significant decline of 17.03% the previous week. Intel's projected revenue for Q1 is between $11.7 billion and $12.7 billion, below analyst expectations [3]. Chinese Stocks - The Nasdaq China Golden Dragon Index decreased by 0.63%, with many popular Chinese stocks declining. Notable drops include Hesai down 10.06% and XPeng down 2.39%, while Li Auto rose 1.38% [3]. Commodity Market - Spot gold prices briefly surpassed $5,000 per ounce and then $5,100 per ounce. Long-term forecasts suggest that gold may continue to perform strongly, indicating a need for portfolio diversification [5]. - The cryptocurrency market saw a collective rise, with Bitcoin surpassing $88,000, while Ethereum increased by 4.14% [6]. Federal Reserve Outlook - The Federal Reserve is expected to announce its first policy decision of the year, with a 97.2% probability of maintaining the current overnight rate. Market speculation includes potential rate cuts later in the year [9].

Group 1 - The Nasdaq China Golden Dragon Index fell by over 0.5% on January 26 [2] - Miniso Group saw a decline of 4.08% [2] - Zai Lab Limited experienced a drop of 4.36% [2] - Daqo New Energy Corp decreased by 2.80% [2] - Xpeng Motors fell by 2.70% [2] - Baidu Inc. declined by 2.51% [2]